Wrapping up Module 2 of the #EASL #MASLD Guidelines Academy in Antwerp 🇧🇪
Two inspiring days of science, discussion and knowledge sharing with leading experts and colleagues from around the world 🌎
A great experience, full of new insights and valuable connections!

A new study finds people who eat after dinner or after bedtime have a significantly higher risk for fatty liver disease and cirrhosis.
youtu.be/1AWoHiGpzfU

#fattyliver #liverhealth #masld #liverdisease #livercirrhosis #cirrhosis #latenighteating #nighttimeeating #eatingbeforebed #eatbeforesleep

Day 1 of Module 2 of the #EASL MASLD Guidelines Academy in
#Antwerp! 🇧🇪
A deeper dive into #MASLD, with inspiring talks, stimulating discussions and great colleagues from 🌎 all over the world.
Always a pleasure to learn, share ideas and exchange experiences with experts in the field! 📚🔬

New study shows empagliflozin and dapagliflozin have comparable risk of liver-related complications, with only marginally greater improvement in fatty liver with empagliflozin, in adults with type 2 diabetes and MASLD. #MASLD #SGLT2i #T2D #LiverHealth link.springer.com/article/10.1...

Ulcerative colitis remission leaves persistent LCN2+ macrophages with heightened glycolysis and H3K9la memory.

#MASLD #GutLiverAxis #LiverSky #Hepatology
https://doi.org/10.1016/j.cmet.2026.09.008

In @eclinicalmed.bsky.social

Dose-dependent efficacy & renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (#MASLD) & hypertriglyceridemia: a multicenter randomized controlled, open label trial www.thelancet.com/journals/ecl....

Can bariatric surgery reduce the risk of fatty liver disease, or #MASLD, and what role can GLP-1s play in the treatment of severe obesity and related medical conditions? #BariatricSurgery

Among patients with #MASLD, although lean patients had fewer metabolic comorbidities and less severe histologic disease mortality and clinical events did not differ significantly from patients with overweight or #obesity.

#liver #BMI

📌 Learn more: ja.ma/4ysP4ik

📘Read in #JExBio📘 Extracellular Vesicle-Based miRNA Profiling in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Secondary Analysis of the MULTISITE Clinical Trial #extracellularvesicles #biomarkers #MASLD #NAFLD isevjournals.onlinelibrary.wiley.com/doi/epdf/10....

Hepatopatía esteatósica asoc a disf metab magra fenotipo c enf histológica más leve y variables clínicas similares a asoc a sobrepeso/obesidad, gravedad de fibrosis asoc c/pronóstico, medición de rigidez hepática es confiable en magros #MASLD #lean jamanetwork.com/journals/jam...

🎥 #AgingShort:
"Adipo-neuroinflammation, cognitive impairment and surrogate markers of cardiovascular risk in patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)”

🔗 https://bit.ly/4wjuAaT

#Aging #TrendingWithImpact #MASLD #BrainHealth #CardiovascularHealth #LiverDisease

📈 #TrendingWithImpact:
"Adipo-neuroinflammation, cognitive impairment and surrogate markers of cardiovascular risk in patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)"

#PressRelease ⬇️
https://bit.ly/4xjU6wL

#Aging #Research #MASLD #OA #Press

La evidencia actual respalda un papel creciente de las terapias basadas en GLP-1 en la enfermedad hepática metabólica y proporciona un marco mecanístico para su continuo desarrollo y evaluación clínica en la #MASLD
https://f.mtr.cool/mapooi3n3y

New FISPGHAN Expert Insights! 🎥 Join Dr. Tania Mitsinikos to explore paediatric metabolic dysfunction-associated steatotic liver disease (MASLD).

Discover barriers to early screening, family care strategies, and policy changes.

🔗 Watch the episode here: youtu.be/YadAh9Xy9dM?...

#ESPGHAN #MASLD

This month, the #SLAMCommunity is hosting its first #VirtualEvent! Register today https://bit.ly/3V6iIet

#SLAM #LiverResearch #MASLD #ALD #Hepatology @harvardmed.bsky.social

#MASLD patients with high cardiovascular risk have more severe #liverfibrosis and higher risk of liver complications, highlighting the need for integrated cardiometabolic and hepatic care.

🔗: https://ow.ly/13B050ZTbXX

In our 2026 special issue: Is #MASLD an independent risk factor for micro- and macrovascular complications of #diabetes? A critical reappraisal and future directions link.springer.com/article/10.1...

In our 2026 special issue: Non-pharmacological treatment of #MASLD link.springer.com/article/10.1...

Welcome to read the Editor´s Choice in October!

➡️Upcoming therapies for steatotic liver disease.
➡️Translating breakthroughs into clinical practice.

🔗 doi.org/10.1111/joim.70143

#liver #MASLD

In our 2026 special issue: #MASLD, #diabetes and #PMOS across the female life stages link.springer.com/article/10.1...